Postpartum hemorrhage (PPH) is a major concern following cesarean birth. Tranexamic acid (TXA) is an antifibrinolytic used to manage PPH, but its effectiveness in preventing PPH is still debated. This review evaluates the use of TXA in preventing PPH during cesarean sections.
In this Cochrane review the authors concluded that :
Prophylactic TXA, when added to standard care during cesarean birth, showed little to no effect on estimated blood loss ≥ 1000 mL but likely reduced calculated blood loss ≥ 1000 mL. There were no significant differences in maternal death, thromboembolic events, or hysterectomy rates. Event rates for blood transfusions, additional uterotonics, and surgical interventions were similar across groups. The evidence for serious adverse events is uncertain, and most studies involved women at low risk for PPH.
Reference:
